Abstract
Backround and aimsAlemtuzumab (Lemtrada ) is a humanized monoclonal anti-CD52 antibody approved for the treatment of patients with relapsing-remitting multiple sclerosis (RRMS). Current information regarding drug induced liver injury (DILI)...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
